Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681324 | 0.87 | THRA (0.49) | PTGDR2THRATHRBFFAR1KMO | |
| SCHEMBL15524659 | 0.83 | RXRA (0.50) | THRATHRBACLYRXRANR1H2 | |
| SCHEMBL30578302 | 0.82 | IDO1 (0.42) | ACLY | |
| SCHEMBL15094094 | 0.82 | POLQ (0.51) | PTGDR2FFAR1KMOFFAR4PPARD | |
| SCHEMBL2393327 | 0.82 | POLB (0.54) | PTGDR2FFAR1KMOFFAR4FFAR2 | |
| SCHEMBL584750 | 0.82 | FFAR1 (0.54) | PTGDR2FFAR1FFAR4 | |
| SCHEMBL5429112 | 0.82 | PPARD (0.42) | PTGDR2THRATHRBFFAR1FFAR4 | |
| SCHEMBL11524595 | 0.81 | MGLL (0.47) | PTGDR2THRATHRBFFAR1FFAR4 | |
| SCHEMBL4007916 | 0.81 | FFAR1 (0.58) | PTGDR2FFAR1KMOFFAR4RXRA | |
| SCHEMBL26008440 | 0.80 | IDO1 (0.39) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2831053-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-8680104-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| EP-1734966-B1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1734966-B1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1734966-A4 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| CN-101035774-A | Modulators of CRTH-2 receptor activity for the treatment of prostaglandin D2 mediated diseases | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| CN-1968698-A | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE SAN DIEGO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1734966-A2 | PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | Incyte Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005101838-A2 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4132737-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | PTGDR2, PTGDR, PTGER2 | PTGDR2 1/4885THRA 562/4885THRB 504/4885 |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | PTGDR2 144/4885THRA 2030/4885THRB 1638/4885 |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | PTGDR2 144/4885THRA 2030/4885THRB 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.